Watch CNBC's full interview with Gilead CEO Daniel O’Day

CNBC's Meg Tirrell sits down with Gilead CEO Daniel O’Day amid the American Society of Clinical Oncology conference in Chicago to discuss the company's latest data surrounding its cancer drug Trodelvy. "We think this data is very important for patients," O’Day tells CNBC. "We'll be moving forward to have discussions with the FDA."